Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Targeting tumor vasculature through oncolytic virotherapy: recent advances.

Toro Bejarano M, Merchan JR.

Oncolytic Virother. 2015 Nov 11;4:169-81. doi: 10.2147/OV.S66045. Review.

2.

Advances in the design and development of oncolytic measles viruses.

Hutzen B, Raffel C, Studebaker AW.

Oncolytic Virother. 2015 Aug 27;4:109-18. doi: 10.2147/OV.S66078. Review.

3.

Recent advances and future of immunotherapy for glioblastoma.

Kamran N, Calinescu A, Candolfi M, Chandran M, Mineharu Y, Asad AS, Koschmann C, Nunez FJ, Lowenstein PR, Castro MG.

Expert Opin Biol Ther. 2016 Oct;16(10):1245-64. doi: 10.1080/14712598.2016.1212012.

4.

Emerging immunotherapies for glioblastoma.

Desai R, Suryadevara CM, Batich KA, Farber SH, Sanchez-Perez L, Sampson JH.

Expert Opin Emerg Drugs. 2016 Jun;21(2):133-45. doi: 10.1080/14728214.2016.1186643.

PMID:
27223671
5.

EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA.

Saha D, Ahmed SS, Rabkin SD.

Drugs Future. 2015;40(11):739-749.

6.

Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy.

Spencer DA, Young JS, Kanojia D, Kim JW, Polster SP, Murphy JP, Lesniak MS.

Ther Deliv. 2015;6(4):453-68. doi: 10.4155/tde.14.123. Review.

7.

Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors.

Studebaker AW, Hutzen B, Pierson CR, Shaffer TA, Raffel C, Jackson EM.

Neuro Oncol. 2015 Dec;17(12):1568-77. doi: 10.1093/neuonc/nov058.

8.

Measles Edmonston vaccine strain derivatives have potent oncolytic activity against osteosarcoma.

Domingo-Musibay E, Allen C, Kurokawa C, Hardcastle JJ, Aderca I, Msaouel P, Bansal A, Jiang H, DeGrado TR, Galanis E.

Cancer Gene Ther. 2014 Nov;21(11):483-90. doi: 10.1038/cgt.2014.54.

9.

Attenuated measles virus controls pediatric acute B-lineage lymphoblastic leukemia in NOD/SCID mice.

Lühl NC, Zirngibl F, Dorneburg C, Wei J, Dahlhaus M, Barth TF, Meyer LH, Queudeville M, Eckhoff S, Debatin KM, Beltinger C.

Haematologica. 2014 Jun;99(6):1050-61. doi: 10.3324/haematol.2013.087205.

10.

A short perspective on gene therapy: Clinical experience on gene therapy of gliomablastoma multiforme.

Wirth T.

World J Exp Med. 2011 Dec 20;1(1):10-6. doi: 10.5493/wjem.v1.i1.10. Review.

11.

Strategies in gene therapy for glioblastoma.

Kwiatkowska A, Nandhu MS, Behera P, Chiocca EA, Viapiano MS.

Cancers (Basel). 2013 Oct 23;5(4):1271-305. doi: 10.3390/cancers5041271.

12.

Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma.

Liu Z, Zhao X, Mao H, Baxter PA, Huang Y, Yu L, Wadhwa L, Su JM, Adesina A, Perlaky L, Hurwitz M, Idamakanti N, Police SR, Hallenbeck PL, Hurwitz RL, Lau CC, Chintagumpala M, Blaney SM, Li XN.

Neuro Oncol. 2013 Sep;15(9):1173-85. doi: 10.1093/neuonc/not065.

13.

DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety.

Friedrich K, Hanauer JR, Prüfer S, Münch RC, Völker I, Filippis C, Jost C, Hanschmann KM, Cattaneo R, Peng KW, Plückthun A, Buchholz CJ, Cichutek K, Mühlebach MD.

Mol Ther. 2013 Apr;21(4):849-59. doi: 10.1038/mt.2013.16.

14.

Oncolytic measles virus strains as novel anticancer agents.

Msaouel P, Opyrchal M, Domingo Musibay E, Galanis E.

Expert Opin Biol Ther. 2013 Apr;13(4):483-502. doi: 10.1517/14712598.2013.749851. Review.

15.

Current status of gene therapy for brain tumors.

Murphy AM, Rabkin SD.

Transl Res. 2013 Apr;161(4):339-54. doi: 10.1016/j.trsl.2012.11.003.

16.

Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine.

Hutzen B, Pierson CR, Russell SJ, Galanis E, Raffel C, Studebaker AW.

BMC Cancer. 2012 Nov 7;12:508. doi: 10.1186/1471-2407-12-508.

17.

The art of gene therapy for glioma: a review of the challenging road to the bedside.

Tobias A, Ahmed A, Moon KS, Lesniak MS.

J Neurol Neurosurg Psychiatry. 2013 Feb;84(2):213-22. doi: 10.1136/jnnp-2012-302946. Review.

18.

Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluid-disseminated medulloblastoma.

Studebaker AW, Hutzen B, Pierson CR, Russell SJ, Galanis E, Raffel C.

Neuro Oncol. 2012 Apr;14(4):459-70. doi: 10.1093/neuonc/nor231.

19.

Measles virus causes immunogenic cell death in human melanoma.

Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, Peach H, Phillips RM, Bond J, Pandha H, Harrington K, Vile R, Russell S, Selby P, Melcher AA.

Gene Ther. 2013 Jan;20(1):7-15. doi: 10.1038/gt.2011.205.

20.

MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism.

Leber MF, Bossow S, Leonard VH, Zaoui K, Grossardt C, Frenzke M, Miest T, Sawall S, Cattaneo R, von Kalle C, Ungerechts G.

Mol Ther. 2011 Jun;19(6):1097-106. doi: 10.1038/mt.2011.55.

Supplemental Content

Support Center